Canadian researchers have launched a clinical trial using oral fecal microbiota transplant pills to improve immunotherapy for lung cancer patients [1].
The study aims to address a critical gap in oncology. While immunotherapy can slow the progression of lung cancer, it does not stop the disease in many patients [1]. By altering the gut microbiome through these pills, researchers hope to enhance the body's immune response to the cancer.
The trial is based in London, Ontario [2]. It represents a significant effort to optimize existing cancer treatments by leveraging the relationship between gut health and the immune system. The process involves delivering fecal microbiota via a pill, a less invasive method than traditional transplant procedures [2].
Financial support for the project comes from a joint investment of $4 million [1]. The funding was provided by the Canadian Cancer Society and the Weston Family Foundation [1].
This initiative is described as the largest clinical trial of its kind in Canada [1]. The researchers are investigating whether the introduction of specific bacteria into the gut can make patients more responsive to immunotherapy drugs, potentially increasing survival rates, or improving the quality of life for those with advanced lung cancer [2].
“The trial is based in London, Ontario.”
This trial explores the emerging field of the microbiome-immune axis. If successful, it could transition fecal microbiota transplants from a niche treatment for intestinal infections into a mainstream adjuvant therapy for oncology, potentially turning non-responsive immunotherapy patients into responders.
